



EARLY PHYSICAL AND PSYCHO-EDUCATIONAL REHABILITATION IN PATIENTS WITH CORONARY ARTERY BYPASS GRAFTING: A RANDOMIZED CONTROLLED TRIAL

Ida Elisabeth HØJSKOV, PhD^{1,2}, Philip MOONS, PhD^{3,4}, Ingrid EGEROD, PhD⁵, Peter Skov OLSEN, Dr. Med. Sci¹, Lau Caspar THYGESEN, PhD⁶, Niels Viggo HANSEN, PhD⁷, Søren LA COUR, MPH, Kristina Hindhede BECH, MSPT⁸, Britt BORREGAARD, MPQM⁸, CHRISTIAN GLUUD, Dr Med Sci⁹, Per WINKEL, Dr Med Sci⁹, Jane LINDSCHOU, MSc⁹ and Selina KIKKENBORG BERG, PhD¹

From the ¹Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, University of Copenhagen, ²Department of Nursing, Faculty of Health and Technology, Metropolitan University College, Copenhagen, Denmark, ³Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium, ⁴Institute of Health and Care Sciences, University of Gothenburg, Gothenburg, Sweden, ⁵Intensive Care Unit, Rigshospitalet, Copenhagen University Hospital, ⁵National Institute of Public Health, University of Southern Denmark, Copenhagen, ¹Interacting Minds Center, Aarhus University, Aarhus, ³Department of Cardiothoracic and Vascular Surgery, Odense University Hospital, Odense and °Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Objectives: Rehabilitation of patients following coronary artery bypass grafting (CABG) has been widely studied; however, research into early rehabilitation after CABG is sparse. The aim of this trial was to assess the impact of early rehabilitation, compared with usual care in patients following CABG.

Design: Randomized controlled trial.

Patients: A total of 326 patients treated with CABG. Methods: Patients treated with CABG were randomized 1:1 to 4 weeks of comprehensive early rehabilitation or usual care. The primary outcome was the Six Minute Walk Test (6MWT). Secondary outcomes were mental health and physical activity (Medical Outcome Study Short Form; SF-12); anxiety and depression (Hospital Anxiety and Depression Scale; HADS); physical and emotional scores; sleep (Pittsburgh Sleep Quality Index; PSQI); pain (Örebro Musculoskeletal Screening Questionnaire; ÖMSQ) and muscle endurance (Sit-To-Stand test).

Results: Sixteen patients dropped out. No significant differences between groups in the primary outcome (6MWT) were found after 4 weeks (p=0.27). For secondary outcomes the odds ratio of HADS-D ≥ 8 decreased in favour of the experimental intervention (p=0.04). There was non-adherence to parts of the intervention. Per-protocol analysis showed differences between groups for the 6MWT (p=0.02) and the Sit-To-Stand test (p=0.046).

Conclusion: In general, the intervention had no effect on the 6MWT, or secondary outcomes, except for depressive symptoms. However, in adherent participants, the intervention had a positive effect for the primary and several secondary outcomes.

Key words: rehabilitation post-CABG; phase 1 rehabilitation; early rehabilitation; coronary artery bypass grafting; physical exercise; psycho-education.

Accepted Oct 2, 2018; Epub ahead of print Nov 28, 2018

J Rehabil Med 2019; 51: 136-143

Correspondence address: Ida Elisabeth Højskov, Department of Cardiothoractic Surgery, Rigshospitalet, University of Copenhagen, The Heart Centre, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Email: ida.elisabeth.hoejskov@regionh.dk

LAY ABSTRACT

This trial investigated the effects of an early rehabilitation programme in addition to usual care for patients undergoing heart bypass surgery. The programme consisted of exercise training and 4 planned nurse consultations in the period from admission to 4 weeks after surgery. The programme was tested by 163 patients undergoing heart bypass surgery, compared with a similar number of patients who followed usual care alone. The trial did not show any effect of the programme on physical function, but there was a positive effect in reducing depressive symptoms in the rehabilitation group. Although the rehabilitation programme was scheduled, adherence was low. The reason for lack of efficacy could be poor adherence to the programme, as patients who followed the programme significantly improved in terms of physical functioning 4 weeks after surgery. The results provide important information for health professionals for refining early rehabilitation programmes after heart bypass surgery.

Cardiac rehabilitation is differentiated into 3 main phases: in-hospital (phase 1); early outpatient (phase 2), and long-term outpatient (phase 3) cardiac rehabilitation (1). Clinical recommendations for phase 1 rehabilitation for patients undergoing coronary artery bypass graft (CABG) surgery are few, and are based on sparse evidence from trials with small sample sizes and non-representative trial populations (2, 3). Patients with chronic conditions can receive surgical treatment (3); however, the postoperative period can be challenging, with physical and psychological problems and symptoms such as anxiety and depression, immobility issues, respiratory complications, insufficient sleep, and fatigue (4–6).

Exercise training after hospital discharge has demonstrated positive benefits (7), and it seems reasonable to start exercise training immediately after CABG surgery (8). Trials have demonstrated improvements in outcomes, measured by pulmonary complications

and physical functional capacity, after CABG (9, 10). Trials targeting psychological and psycho-educational interventions in patients undergoing rehabilitation have shown improvements in symptoms of depression and anxiety (11); however, no published randomized controlled trial using phase 1 rehabilitation for CABG patients has had an adequate sample size (12). A pilot trial was conducted to evaluate acceptability of inclusion, feasibility and intervention compliance, which showed high inclusion, feasibility and safety, but moderate compliance with the physical and the psychoeducational interventions (13). It was hypothesized that comprehensive cardiac rehabilitation would increase physical functioning and improve mental health.

The aim of the trial was to assess the impact of phase 1 rehabilitation and early phase 2 rehabilitation, prospectively named early rehabilitation, compared with usual care, in patients undergoing CABG based on the primary outcome of physical function and on secondary outcomes of physical and mental health, anxiety, depression, sleep, pain and health-related quality of life.

METHODS

The SheppHeartCABG trial ("Shaping outcomes by Exercise training and Psychoeducation in Phase 1 for Heart patients") is an investigator-initiated randomized controlled trial (RCT) (14). The trial followed the principles of the Declaration of Helsinki and was approved by the Regional Ethics Committee (H-4-2014-109) and the Danish Data Protection Agency (30-1309). The trial was registered at ClinicalTrials.gov (NCT02290262) and reported according to the Consolidated Standards of Reporting Trials (CONSORT).

Participants, setting and recruitment

The settings were thoracic clinics at 2 university hospitals in Denmark: Odense and Copenhagen. Patients were screened consecutively for inclusion. First-time elective patients undergoing CABG who provided informed consent were included. Patients younger than 18 years of age, patients diagnosed with a musculoskeletal or neurological disease precluding exercise testing and training, and patients who did not speak Danish were excluded. Potential participants received verbal and written information at admission and were recruited over a period of 19 months.

Randomization and blinding

Randomization was 1:1 by central randomization, with the allocation

sequence computer-generated using blocks varying between 4, 6, 8, 10, 12, and 14, stratified according to site and sex, and concealed from the investigators, as allocation was done through a web-based system. Full blinding of clinicians and participants is impossible in a rehabilitation trial, but data collection, outcome assessment, data management, statistical analyses, and conclusions were blinded to the allocation group.

Intervention group

An outline of the trial interventions (14) is shown in Fig. 1 including the intervention components, the timeline for the 2 groups, and the outcome measures.

Physical exercise component

The aim of the physical intervention was to improve physical functioning 4 weeks after CABG. The physical rehabilitation programme was initiated the day before surgery. Patient-reported diaries and a heart-rate monitor were used to monitor. The physical interventions were administrated by physiotherapists and included an exercise programme starting at admission and continued for 4 weeks after CABG. The physical intervention was divided into respiratory physiotherapy and aerobic training. After hospital discharge, until 4 weeks after CABG, exercise included continuous daily walking and muscle and endurance exercises (Fig. 1).

Psycho-educational component

The aim of the psycho-educative intervention was to improve disease coping by applying a patient-centred approach. The conceptual foundation for dialogue with patients was based on the Human Becoming Practice Methodologies by Parse (15). The consultations were performed by 6 trained nurses and most participants met the same nurse at all consultations. A




Fig. 1. Trial design.

consultation guide was followed to ensure intervention fidelity and the nurses were supervised regularly (13). The psychoeducative intervention consisted of 4 face-to-face consultations. Mindfulness was an integral element in the psycho-educational consultation and was provided as a toolbox of recorded meditation instructions for personal use, e.g. as an alternative to medication for sleep disorders and physically and emotionally stressful situations (14).

Control group

All patients in the control group followed usual care procedures (16), which included medical follow-up and standard treatment according to disease-specific guidelines (2). Admission time after CABG is between 5 and 8 days. Usual care includes preoperative and postoperative information provided by physicians, nurses and physiotherapist. Instructions regarding precautions after sternotomy are pre-operatively supplied by physiotherapists covering the immediate postoperative period during hospitalization. Close to discharge the physiotherapists introduced and informed the patients about how to be physically active, but still pretecting the sternum. The main topics of preoperative nursing are: an admission interview, followed by postoperative screening (falls, nutrition); introduction to postoperative pain and nausea medications; pain assessment and postoperative activities. Initial postoperative care focuses on observation of vital signs. The subsequent time in hospital focuses on recovery and preparation for discharge.

Outcomes

Outcome assessment was carried out at 3 time-points: baseline; discharge; and 4 weeks post-CABG.

Primary outcome: physical function. Physical functioning at 4 weeks following CABG was measured with the Six Minute Walk Test (6MWT) (17). Participants walked up and down a 30-m hallway for 6 min according to guidelines (18).

Secondary outcomes. The secondary outcomes were physical activity and mental health measured by the Medical Outcome

Study Short Form (SF-12) (19), anxiety and depression by the Hospital Anxiety and Depression Scale (HADS) questionnaire (20), physical, emotional and global scores by the HeartQoL questionnaire (21), sleep expressed by the Pittsburgh Sleep Quality Index (PSQI) (22), pain evaluated by the Örebro Musculoskeletal Screening Questionnaire (ÖMSQ) (23), and muscle endurance measured by a Sit-To-Stand test (24).

Safety considerations

The 6MWT was administered by a nurse or a physiotherapist at baseline and by physiotherapists at discharge and 4 weeks after surgery, with defined criteria for termination (18). Serious adverse events were registered and discussed with the responsible physician and primary investigator.

Sample size

Sample size was calculated to comprise 326 participants based on the expectation

of achieving an improvement in 6MWT by 30 m, a standard deviation of 90 m, with alpha of 5% and a power of 85%. The anticipated improvement in the intervention group is assumed to be feasible because the SheppHeartCABG pilot (13) showed a mean of 548 m in the intervention group and 451 m in the control group measured by 6MWT.

Statistical analysis

Intention-to-treat analyses were used. There were 2 types of comparisons between the intervention groups: (i) comparison of values at week 4 after surgery, this analysis used a general univariate linear model (excepting HeartQol and HADS (see below) adjusted for baseline values and stratifying variables (sex and site)) and (ii) comparison of values at discharge and at 4 weeks. This analysis used a mixed linear model including an unstructured covariance matrix. In this model, the interaction between intervention and time was of principal interest. This analysis was adjusted for baseline values and stratifying variables (sex and site). If the assumptions of the models were not fulfilled with reasonable approximation, removal of outliers and transformation of outcome were performed. HeartQol quantities were converted to binary quantities based on the median score among available cases. HADS was reported as mean and standard deviation and converted to binary quantities (score \geq 8) as probable anxiety or depression. For both outcomes, logistic regression models were used to compare the experimental and control group (usual care) at 4 weeks, adjusted for value at baseline. Since almost all secondary outcomes were overpowered (14), Cohen's d was calculated for primary and secondary outcomes as a measure of effect size.

For the primary and secondary outcomes, multiple imputation of missing values using the Markov chain Monte Carlo approach was carried out, since the number of participants with missing values was above 5%. The variables included group, stratifying variables (site and sex), time (baseline, discharge and 4 weeks after discharge) and all outcomes. The primary outcome (6MWT) was tested using a significance level of 0.05. Analyses of the secondary outcome measures as pre-planned




Fig. 2. Flow of patients in the SheppHeartCABG trial. Consolidated Standard of Reporting Trials (CONSORT) flow diagram.

in the protocol were analysed with no adjustment of *p*-values due to multiplicity. Instead, the interpretation of each secondary outcome measure was assessed in the light of multiple testing.

The pre-specified per-protocol level of intervention adherence was defined (14) as completing at least 75% of the exercise sessions and consultations and using one of the mindfulness tools on 75% of the days. However, only one participant reached that level. Therefore, it was decided before the start of analysis to change the per-protocol level to participation in at least 50% of the exercise sessions and psycho-educational consultations. Adherence to the exercise intervention was assessed using the patient-reported exercise diary, and the recordings made for the psycho-educational intervention at each visit.

Statistical analyses were conducted in SPSS V.22 (SPSS Inc. IBM), R version 3.1.2 (R Foundation for Statistical Computing, Vienna Austria) and SAS V.9.3 (SAS Institute, Cary, NC, USA).

RESULTS

Between November 2014 and June 2016, 717 patients were identified and screened. A total of 277 patients were excluded and 114 of the remaining 440 participants (26%) declined to participate. A total of 326 patients were randomized (Fig. 2).

Baseline characteristics

The sex ratio was equal among those patients who declined to participate and the included patients. In the randomized group 11 patients dropped out from the experimental group and 5 from the usual care group (control group). Of the 310 remaining patients, 87% were men, with a mean age of 65 years (range 33–83 years). NYHA class ranged from I to IV (Table I).

Outcomes

Primary outcome. There was no statistically significant difference between the experimental and control groups at 4 weeks after CABG on 6MWT (16.2 m (95% confidence interval (CI): -13.0 to 45.4 m), p=0.27) and no significant interaction between intervention and time was observed (p=0.55). Cohen's d was 0.14 (Table II).

Secondary outcomes. Testing the secondary outcomes no p-value less than 0.05 was observed, except a difference in favour of the experimental intervention detected on HADS-D \geq 8 (odds ratio=0.46 (95% CI: 0.22 to 0.97), p=0.04) (Tables II and III). The secondary outcomes showed a tendency toward better scores in the experimental group on all outcomes except SF-12 PCS (Physical Component Scale).

Adherence

In the intervention group, 110/152 (72%) patients participated in the exercise training programme with the

Table I. Baseline characteristics: experimental group and control group

Age, years, mean (SD) 65.0 (9.1) 65.1 (8.4) Male, n (%) 132 (87) 136 (86) Female, n (%) 20 (13) 22 (14) Marital status, n (%) 32 (21) 37 (23) Married/domestic partner 120 (79) 121 (77) Occupational status, n (%) 46 (40) 80 (51) Active employment 61 (40) 80 (51) Retired 86 (56) 76 (48) Early retirement 4 (3) 1 (1) Person on job release scheme 1 (1) 1 (1) Educational level 68 (45) 90 (57) College 37 (24) 31 (20) University 34 (22) 22 (14) None 2 (1) 2 (1) College 37 (24) 31 (20) Unisclosed 11 (7) 13 (8) Body mass index (kg/m²), n (%) (2 (1) 2 (1) < 18.5 1 (1) 1 (0.6) ≥ 18.5 < 25 39 (26) 35 (22) ≥ 25 < 30 65 (42) 77 (49)	group		
Male, n (%) 20 (13) 22 (14) Married, n (%) 20 (13) 22 (14) Married status, n (%) Single/divorced/widowed 32 (21) 37 (23) Married/domestic partner 120 (79) 121 (77) Occupational status, n (%) Active employment 61 (40) 80 (51) Retired 86 (56) 76 (48) Early retirement 4 (3) 1 (1) Person on job release scheme 1 (1) 1 (1) Educational level, n (%) Vocational level, n (%) Vocational level 68 (45) 90 (57) College 37 (24) 31 (20) University 34 (22) 22 (14) None 2 (1) 2 (1) Undisclosed 11 (7) 13 (8) Body mass index (kg/m²), n (%) <18.5 1 (1) 1 (0.6) ≤18.5 225 39 (26) 35 (22) ≥25 <30 65 (42) 77 (49) >30 46 (30) 40 (25) Undisclosed 1 (1) 5 (3) Undisclosed 46 (37) 47 (30) NYHA class II 44 (29) 41 (26) NYHA class II 51 (34) 60 (38) NYHA class IV 2 (1) 5 (3) Undisclosed 2 (14) 21 (13) Undisclosed 2 (14) 21 (13) Undisclosed 2 (14) 21 (13) Undisclosed 2 (17) 4 (30) NYHA class IV 2 (1) 5 (3) Undisclosed 2 (14) 21 (13) Undisclosed 2 (17) 4 (30) NYHA class II 30 (20) 31 (20) MYHA class			
Male, n (%) 20 (13) 22 (14) Married, n (%) 20 (13) 22 (14) Married status, n (%) Single/divorced/widowed 32 (21) 37 (23) Married/domestic partner 120 (79) 121 (77) Occupational status, n (%) Active employment 61 (40) 80 (51) Retired 86 (56) 76 (48) Early retirement 4 (3) 1 (1) Person on job release scheme 1 (1) 1 (1) Educational level, n (%) Vocational level, n (%) Vocational level 68 (45) 90 (57) College 37 (24) 31 (20) University 34 (22) 22 (14) None 2 (1) 2 (1) Undisclosed 11 (7) 13 (8) Body mass index (kg/m²), n (%) <18.5 1 (1) 1 (0.6) ≤18.5 225 39 (26) 35 (22) ≥25 <30 65 (42) 77 (49) >30 46 (30) 40 (25) Undisclosed 1 (1) 5 (3) Undisclosed 46 (37) 47 (30) NYHA class II 44 (29) 41 (26) NYHA class II 51 (34) 60 (38) NYHA class IV 2 (1) 5 (3) Undisclosed 2 (14) 21 (13) Undisclosed 2 (14) 21 (13) Undisclosed 2 (14) 21 (13) Undisclosed 2 (17) 4 (30) NYHA class IV 2 (1) 5 (3) Undisclosed 2 (14) 21 (13) Undisclosed 2 (17) 4 (30) NYHA class II 30 (20) 31 (20) MYHA class	Age, years, mean (SD)	65.0 (9.1)	65.1 (8.4)
Female, n (%) 20 (13) 22 (14) Marital status, n (%) 32 (21) 37 (23) Married/domestic partner 120 (79) 121 (77) Occupational status, n (%) 40 80 (51) Retired 86 (56) 76 (48) Early retirement 4 (3) 1 (1) Person on job release scheme 1 (1) 1 (1) Educational level, n (%) Vocational level 68 (45) 90 (57) College 37 (24) 31 (20) University 34 (22) 22 (14) None 2 (1) 2 (1) Undisclosed 11 (7) 13 (8) Body mass index (kg/m²), n (%) < 18.5 ≤ 25 39 (26) 35 (22) ≥ 25 < 30 65 (42) 77 (49) > 30 46 (30) 40 (25) Undisclosed 1 (1) 5 (3) Type of heart disease 102 (67) 106 (67) Others 3 (2) Undisclosed 46 (37) 47 (30) NYHA class II 44 (29) 41 (26) NYHA class II 51 (34) 60 (38) NYHA class II 51 (34) 60 (38) NYHA class II 30 (20) 31 (20) NYHA class II 51 (34) 60 (38) NYHA class II 51 (34) 60 (38) NYHA class II 51 (34) 60 (38) NYHA class II 90 (20) 31 (20) NYHA class II 90 (20) 31 (20) NYHA class II 151 (34) 60 (38) NYHA class II 151 (34) 60 (38) NYHA class II 151 (34) 60 (38) NYHA class II 90 (20) 31 (20) NYHA class II 90 (20			
Marital status, n (%) 32 (21) 37 (23) Married/domestic partner 120 (79) 121 (77) Occupational status, n (%) 4 (40) 80 (51) Active employment 61 (40) 80 (51) Retired 86 (56) 76 (48) Early retirement 4 (3) 1 (1) Person on job release scheme 1 (1) 1 (1) Educational level, n (%) 7 (24) 31 (20) Vocational level 68 (45) 90 (57) College 37 (24) 31 (20) University 34 (22) 22 (14) None 2 (1) 2 (1) University 34 (22) 22 (14) None 2 (1) 2 (1) Unidisclosed 11 (7) 13 (8) Body mass index (kg/m²), n (%) (3) 4 (8.5) 1 (1) 1 (0.6) ≥ 18.5 1 (1) 1 (0.6) ≥ 18.5 1 (1) 1 (0.6) ≥ 2.5 < 30			
Single/divorced/widowed 32 (21) 37 (23) Married/domestic partner 120 (79) 121 (77) Occupational status, n (%) 4 (30) 1 (1) Active employment 61 (40) 80 (51) Retired 86 (56) 76 (48) Early retirement 4 (3) 1 (1) Person on job release scheme 1 (1) 1 (1) Educational level, n (%) Vocational level 68 (45) 90 (57) College 37 (24) 31 (20) University 34 (22) 22 (14) None 2 (1) 2 (1) University 34 (22) 22 (14) Body mass index (kg/m²), n (%) < 11 (7)		` '	, ,
Occupational status, n (%) Active employment 61 (40) 80 (51) Retired 86 (56) 76 (48) Early retirement 4 (3) 1 (1) Person on job release scheme 1 (1) 1 (1) Educational level, n (%) Vocational level 68 (45) 90 (57) College 37 (24) 31 (20) University 34 (22) 22 (14) None 2 (1) 2 (1) Undisclosed 11 (7) 13 (8) Body mass index (kg/m²), n (%) <18.5 1 (1) 1 (0.6) ≥18.5 < 25 39 (26) 35 (22) ≥25 < 30 46 (30) 40 (25) Undisclosed 1 (1) 5 (3) Undisclosed 1 (1) 5 (3) Type of heart disease, n (%) Ischaemic heart disease 102 (67) 106 (67) Others 3 (2) 5 (3) Undisclosed 46 (37) 47 (30) NYHA class I 44 (29) 41 (26) NYHA class II 51 (34) 60 (38) NYHA class II 51 (34) 70 (30) NORMER (30 (30 (30 (30 (30 (30 (30 (30 (30 (30		32 (21)	37 (23)
Active employment			
Retired 86 (56) 76 (48) Early retirement 4 (3) 1 (1) Person on job release scheme 1 (1) 1 (1) Educational level, n (%) Vocational level 68 (45) 90 (57) College 37 (24) 31 (20) University 34 (22) 22 (14) None 2 (1) 2 (1) Undisclosed 11 (7) 13 (8) Body mass index (kg/m²), n (%) < 18.5 1 (1) 1 (0.6) ≥ 18.5 < 25 39 (26) 35 (22) ≥ 25 < 30 65 (42) 77 (49) > 30 46 (30) 40 (25) Undisclosed 1 (1) 5 (3) Type of heart disease, n (%) Ischaemic heart disease 102 (67) 106 (67) Others 3 (2) 5 (3) Undisclosed 46 (37) 47 (30) NYHA class, n (%) NYHA class II 51 (34) 60 (38) NYHA class II 30 (20) 31 (20) NYHA class II 90 (30) (30) (30) Undisclosed 22 (14) 21 (13) LVEF, n (%) Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35) 9 (6) 20 (13) Undisclosed 2 (1) 4 (3) Smoker, n (%) Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Type I 6 (4) 7 (4) Type I 29 (19) 40 (25) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)			
Early retirement	Active employment	61 (40)	80 (51)
Early retirement			
Educational level, n (%) Vocational level 68 (45) 90 (57) College 37 (24) 31 (20) University 34 (22) 22 (14) None 2 (1) 2 (1) Undisclosed 11 (7) 13 (8) Body mass index (kg/m²), n (%) <18.5 1 (1) 1 (0.6) ≥18.5 < 25 39 (26) 35 (22) ≥25 < 30 65 (42) 77 (49) >30 46 (30) 40 (25) Undisclosed 1 (1) 5 (3) Type of heart disease, n (%) Ischaemic heart disease 102 (67) 106 (67) Others 3 (2) 5 (3) Undisclosed 46 (37) 47 (30) NYHA class, n (%) NYHA class II 44 (29) 41 (26) NYHA class III 51 (34) 60 (38) NYHA class III 30 (20) 31 (20) NYHA class IV 2 (1) 5 (3) Undisclosed 22 (14) 21 (13) LVEF, n (%) Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35) 9 (6) 20 (13) Undisclosed 2 (1) 4 (3) Smoker, n (%) Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Type II 99 (19) 40 (25) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Blood pressure-lowering drugs 40 (50) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)	Early retirement	4 (3)	1 (1)
Vocational level 68 (45) 90 (57) College 37 (24) 31 (20) University 34 (22) 22 (14) None 2 (1) 2 (1) Undisclosed 11 (7) 13 (8) Body mass index (kg/m²), n (%) 3 (1) 3 (2) ≤ 18.5 39 (26) 35 (22) ≥ 25 < 30	Person on job release scheme	1 (1)	1 (1)
College 37 (24) 31 (20) University 34 (22) 22 (14) None 2 (1) 2 (1) Undisclosed 11 (7) 13 (8) Body mass index (kg/m²), n (%) <18.5 1 (1) 1 (0.6) ≥18.5 <25 39 (26) 35 (22) ≥25 <30 65 (42) 77 (49) >30 46 (30) 40 (25) Undisclosed 1 (1) 5 (3) Type of heart disease, n (%) Ischaemic heart disease 102 (67) 106 (67) Others 3 (2) 5 (3) Undisclosed 46 (37) 47 (30) NYHA class, n (%) NYHA class II 51 (34) 60 (38) NYHA class II 51 (34) 60 (38) NYHA class II 30 (20) 31 (20) NYHA class II 30 (20) 31 (20) NYHA class II 51 (34) 60 (38) NYHA class II 75 (34) 10 (67) Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35) 9 (6) 20 (13) Undisclosed 2 (1) 4 (3) Smoker, n (%) Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Antiplatelet drugs 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)	Educational level, n (%)		
University None 2 (1) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1) 3 (8) 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	Vocational level	68 (45)	90 (57)
None Undisclosed Body mass index (kg/m²), n (%) <18.5 ≥18.5 < 1 (1)	College	37 (24)	31 (20)
Undisclosed Body mass index (kg/m²), n (%) <18.5 ≥18.5 < 25 ≥25 < 30 65 (42) 77 (49) >30 46 (30) 40 (25) Undisclosed 1 (1) 5 (3) Type of heart disease, n (%) Ischaemic heart disease 102 (67) Others 3 (2) 5 (3) Undisclosed 46 (37) NYHA class, n (%) NYHA class II 51 (34) NYHA class III 70 (30) NYHA class III 70 (30) NYHA class IV 70 (1) 70 (2) 70 (2) 70 (3) 70 (4) 70 (4) 70 (4) 70 (7)	University	34 (22)	22 (14)
Body mass index (kg/m²), n (%) <18.5 1 (1) 1 (0.6) ≥18.5 < 25 39 (26) 35 (22) ≥25 < 30 65 (42) 77 (49) >30 46 (30) 40 (25) Undisclosed 1 (1) 5 (3) Type of heart disease, n (%) Ischaemic heart disease 102 (67) 106 (67) Others 3 (2) 5 (3) Undisclosed 46 (37) 47 (30) NYHA class I 44 (29) 41 (26) NYHA class II 51 (34) 60 (38) NYHA class II 30 (20) 31 (20) NYHA class II 30 (20) 31 (20) NYHA class IV 2 (1) 5 (3) Undisclosed 22 (14) 21 (13) LVEF, n (%) Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35) 9 (6) 20 (13) Undisclosed 2 (1) 4 (3) Smoker, n (%) Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Type I 6 (4) 7 (4) Type I 9 (9) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)	None	2 (1)	2 (1)
<18.5 ≥18.5 < 25 39 (26) 35 (22) ≥25 < 30 65 (42) 77 (49) >30 46 (30) 40 (25) Undisclosed 1 (1) 5 (3) Type of heart disease, n (%) Ischaemic heart disease 102 (67) 106 (67) Others 3 (2) 5 (3) WHA class, n (%) NYHA class, n (%) NYHA class II 44 (29) 41 (26) NYHA class II 51 (34) 60 (38) NYHA class II 30 (20) 31 (20) NYHA class II 30 (20) 31 (20) NYHA class II 30 (20) 31 (20) NYHA class IV 2 (1) 5 (3) Undisclosed 22 (14) 21 (13) LVEF, n (%) Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35) 9 (6) 20 (13) Undisclosed 2 (1) 4 (3) Smoker, n (%) Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Type I 6 (4) 7 (4) Type I 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)	Undisclosed	11 (7)	13 (8)
≥ 18.5 < 25 ≥ 25 < 30 ≥ 25 < 30 ≥ 25 < 30 ≥ 30	Body mass index (kg/m 2), n (%)		
≥ 25 < 30	< 18.5	1 (1)	1 (0.6)
> 30	≥ 18.5 < 25	39 (26)	35 (22)
Undisclosed 1 (1) 5 (3) Type of heart disease, n (%) Ischaemic heart disease 102 (67) 106 (67) Others 3 (2) 5 (3) Undisclosed 46 (37) 47 (30) NYHA class, n (%) NYHA class I 44 (29) 41 (26) NYHA class II 51 (34) 60 (38) NYHA class III 30 (20) 31 (20) NYHA class IV 2 (1) 5 (3) Undisclosed 22 (14) 21 (13) LVEF, n (%) Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (< 35) 9 (6) 20 (13) Undisclosed 2 (1) 4 (3) Smoker, n (%) Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)	≥ 25 < 30	65 (42)	77 (49)
Type of heart disease, n (%) Ischaemic heart disease 102 (67) 106 (67) Others 3 (2) 5 (3) Undisclosed 46 (37) 47 (30) NYHA class, n (%) NYHA class I 44 (29) 41 (26) NYHA class II 51 (34) 60 (38) NYHA class III 30 (20) 31 (20) NYHA class IV 2 (1) 5 (3) Undisclosed 22 (14) 21 (13) LVEF, n (%) Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35) 9 (6) 20 (13) Undisclosed 2 (1) 4 (3) Smoker, n (%) Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)	> 30	46 (30)	40 (25)
Ischaemic heart disease 102 (67) 106 (67) Others 3 (2) 5 (3) Undisclosed 46 (37) 47 (30) NYHA class, n (%) *** NYHA class I 44 (29) 41 (26) NYHA class III 51 (34) 60 (38) NYHA class III 30 (20) 31 (20) NYHA class IV 2 (1) 5 (3) Undisclosed 22 (14) 21 (13) LVEF, n (%) ** ** Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35)	Undisclosed	1 (1)	5 (3)
Others 3 (2) 5 (3) Undisclosed 46 (37) 47 (30) NYHA class, n (%) *** NYHA class I 44 (29) 41 (26) NYHA class III 51 (34) 60 (38) NYHA class III 30 (20) 31 (20) NYHA class IV 2 (1) 5 (3) Undisclosed 22 (14) 21 (13) LVEF, n (%) ** ** Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35)	Type of heart disease, n (%)		
Undisclosed 46 (37) 47 (30) NYHA class, n (%) NYHA class I 44 (29) 41 (26) NYHA class II 51 (34) 60 (38) NYHA class III 30 (20) 31 (20) NYHA class IV 2 (1) 5 (3) Undisclosed 22 (14) 21 (13) LVEF, n (%) Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35) 9 (6) 20 (13) Undisclosed 2 (1) 4 (3) Smoker, n (%) Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)	Ischaemic heart disease	102 (67)	106 (67)
NYHA class I	Others	3 (2)	5 (3)
NYHA class I		46 (37)	47 (30)
NYHA class II 51 (34) 60 (38) NYHA class III 30 (20) 31 (20) NYHA class IV 2 (1) 5 (3) Undisclosed 22 (14) 21 (13) LVEF, n (%) Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35) 9 (6) 20 (13) Undisclosed 2 (1) 4 (3) Smoker, n (%) Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) Blood pressure-lowering drugs ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)			
NYHA class III 30 (20) 31 (20) NYHA class IV 2 (1) 5 (3) Undisclosed 22 (14) 21 (13) LVEF, n (%) Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35) 9 (6) 20 (13) Undisclosed 2 (1) 4 (3) Smoker, n (%) Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) Blood pressure-lowering drugs ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)			. ,
NYHA class IV Undisclosed LVEF, n (%) Normal (50-70) Reduced (36-49) Low (<35) Undisclosed 20 (11) Low (<35) Undisclosed 20 (11) Low (<35) Undisclosed 20 (13) Undisclosed 20 (13) Undisclosed 20 (13) Current smoker 20 (13) Previous smoker 20 (13) Previous smoker 20 (13) 26 (16) Previous fellitus, n (%) Type I 20 (14) Type II 20 (15) Undisclosed 20 (16) Type II 20 (17) Type II 20 (18) Type II 20 (19) Roberts deliction, n (%) Prescribed medication, n (%) Blood pressure-lowering drugs ACE inhibitor 26 (17) Beta-blocker 42 (28) ACE inhibitor 26 (17) Beta-blocker 42 (28) ACE inhibitor 33 (22) Antiarrhythmic drugs Antiarrhythmic drugs Aliarrhythmic drugs Aliarrhythmic drugs Antiarrhythmic drugs 126 (83) Antiarrhythmic drugs Antidepressant P (6) Pain reliever 21 (14) 29 (18)			. ,
Undisclosed 22 (14) 21 (13) LVEF, n (%) Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35) 9 (6) 20 (13) Undisclosed 2 (1) 4 (3) Smoker, n (%) Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)			
LVEF, n (%) Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35) 9 (6) 20 (13) Undisclosed 2 (1) 4 (3) Smoker, n (%) Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)		, ,	
Normal (50-70) 112 (74) 106 (67) Reduced (36-49) 29 (19) 28 (17) Low (<35)		22 (14)	21 (13)
Reduced (36-49) 29 (19) 28 (17) Low (<35)			
Low (<35)			
Undisclosed 2 (1) 4 (3) Smoker, n (%) Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)		. ,	
Smoker, n (%) 20 (13) 26 (16) Current smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) 7 (4) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) 87 (57) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)			
Current smoker 20 (13) 26 (16) Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) 7 (4) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) 8000 pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)		2 (1)	4 (3)
Previous smoker 79 (52) 86 (54) Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) 7 (4) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) 800 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)		20 (12)	26 (16)
Undisclosed 2 (1) 2 (1) Diabetes mellitus, n (%) 7 (4) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) Pescribed medication, n (%) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)			
Diabetes mellitus, n (%) Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) Blood pressure-lowering drugs 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)			
Type I 6 (4) 7 (4) Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) 8 Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)		2 (1)	2 (1)
Type II 29 (19) 40 (25) Undisclosed 1 (0.7) 0 Prescribed medication, n (%) 87 (57) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)		6 (4)	7 (4)
Undisclosed 1 (0.7) 0 Prescribed medication, n (%) 80 (59) 87 (57) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)	* *		
Prescribed medication, n (%) Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)			
Blood pressure-lowering drugs 90 (59) 87 (57) ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)		1 (0.7)	U
ACE inhibitor 26 (17) 32 (20) Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)		00 (E0)	07 (E7)
Beta-blocker 42 (28) 42 (27) Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)			
Calcium antagonist 33 (22) 37 (23) Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)			
Antiarrhythmic drugs 3 (2) 2 (1) Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)			
Antiplatelet drugs 126 (83) 134 (84) Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)			. ,
Diuretic 27 (18) 43 (27) Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)	, -		. ,
Anti-diabetic 24 (16) 0 (0) Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)	, ,		
Statin 126 (83) 131 ((83) Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)			
Antidepressant 9 (6) 10 (6) Pain reliever 21 (14) 29 (18)		. ,	
Pain reliever 21 (14) 29 (18)			
` ,		, ,	
			. ,

LVEF: left ventricular ejection fraction; NYHA: New York Heart Association Functional Classification.

number of sessions completed depending on length of hospitalization. Sixteen (15%) participants conducted \geq 75% of the training programme, 35 patients (32%) 50–74%, and 59 (54%) patients carried out <50% of

Table II. Mean difference in outcome and odds ratio between experimental group and control group

	n	Estimate Mean (95% CI)	<i>p</i> -value	SD	Cohen's d
Primary outcomes					
6-MWT	310	16.2 (-13.0; 45.4)	0.27	119.8	0.14
Secondary outcomes					
SF-12 mental	310	1.18 (-1.74; 4.09)	0.43	11.8	0.10
SF-12 physical	310	-0.82 (-3.18; 1.54)	0.49	10.2	-0.08
Pittsburgh Sleep QI	310	-0.91 (-2.06; 0.23)	0.12	4.6	-0.20
Örebro MSQ	310	-1.92 (-4.34; 0.51)	0.12	10.9	-0.18
Sit-To-Stand test	310	1.09 (-0.34; 2.52)	0.13	5.0	0.22
HADS anxiety	310	-0.59 (-1.50; 0.32)	0.20	4.0	-0.15
HADS depression	310	-0.43 (-1.33; 0.46)	0.34	3.8	-0.11
Binary outcomes		OR (95% CI)			
HADS anxiety (8+)	310	0.62 (0.29; 1.29)	0.20		
HADS depression (8+)	310	0.46 (0.22; 0.97)	0.04		
HeartQol (> median)					
HeartQol global	310	0.78 (0.45; 1.35)	0.37		
HeartQol emotional	310	0.93 (0.42; 2.09)	0.86		

Effect size Cohen's d: 0.20 = small; 0.50 = medium; 0.80 = large. SD: standard deviation; MWT Minute Walk Test; QI: Quality Index: HADS: Hospital Anxiety and Depression Scale; MSQ: Musculoskeletal Screening Questionnaire; CI: Confidence intervals

Table III. HADS-anxiety and HADS-depression in experimental and control groups

Secondary outcomes	n	Group		Discharge Mean (SD)	4 weeks after surgery
HADS anxiety	310	Experimental	5.4 (4.3)	5.7 (4.0)	3.5 (3.4)
		Control	6.0 (4.5)	5.8.(4.3)	4.3 (3.7)
HADS depression	310	Experimental	4.0 (3.5)	5.8 (3.7)	3.7 (3.2)
		Control	3.9 (3.5)	5.7 (4.1)	4.3 (3.7)

HADS: Hospital Anxiety and Depression Scale; SD: standard deviation.

the sessions. The patients participated in 65% (median 68) of the training programme during admission and 54% (median 63) after discharge.

All participants in the experimental group participated in the psycho-educational intervention, of whom 115/152 (76%) attended all 4 consultations. Regarding mindfulness 91/152 (60%) participated in the introduction given as part of the psycho-educational consultation. Of these, 2 patients (2%) used the mindfulness toolbox exercises on $\geq 75\%$ of the following days in hospital, 10 (11%) on 50-74% of the days and 79 (86%) used them rarely or not at all.

Per-protocol analysis

Per-protocol analysis was performed on patients who completed more than 50% of the exercise training programme in and out of hospital and the psychoeducational consultations (n=51 (34%)). There was a difference between the experimental and control group on the 6MWT as primary outcome (41.1 m (95% CI 8.0–74.3 m), p=0.02) and on 1 of the secondary outcomes, the Sit-To-Stand test (1.87 repetitions (95% CI 0.04–3.70 repetitions), p=0.046) 4 weeks after surgery. These differences corresponded with a Cohen's d of

Table IV Results of per-protocol. The estimates are the mean difference in outcome and odds ratio between experimental and control groups

	n	Estimate Mean (95% CI)	<i>p</i> -value	Cohen's d
Primary outcome				
6MWT	209	41.1 (8.0; 74.3)	0.02	0.40
Secondary outcomes SF-12 mental SF-12 physical Pittsburgh Sleep QI Örebro MSQ Sit-To-Stand test	209 209 209 209 209	1.84 (-1.80; 5.49) -1.50 (-4.69; 1.70) -1.49 (-3.02; 0.04) -3.54 (-6.92; -0.17) 1.87 (0.04; 3.70)	0.32 0.36 0.06 0.04 0.046	0.17 -0.16 -0.31 -0.34 0.36
Binary outcomes HADS anxiety (8+) HADS depression (8+)	209 209	OR (95% CI) 0.56 (0.20; 1.52) 0.46 (0.17; 1.27)	0.25 0.13	
HeartQol (>median) HeartQol global HeartQol physical HeartQol emotional	209 209 209	0.76 (0.36; 1.61) 0.70 (0.34; 1.41) 0.87 (0.42; 1.82)	0.48 0.32 0.72	

MWT Minute Walk Test; QI: Quality Index: HADS: Hospital Anxiety and Depression Scale; MSQ: Musculoskeletal Screening Questionnaire; CI: Confidence intervals.

0.40 and 0.36, respectively (Table IV). The remaining secondary outcomes, showed no significant differences.

Safety

One serious adverse event was reported at baseline in the experimental group after administering the 6MWT. The participant had 2 episodes of ventricular tachycardia after ending the 6MWT. The event was evaluated to be independent of the 6MWT. There were no serious adverse events in the control group.

DISCUSSION

To the best of our knowledge, this is the largest randomized controlled trial to examine the effect of a comprehensive early rehabilitation programme including a physical and a psychological component in patients who have undergone CABG surgery. The intervention appeared safe, with only one serious event, which was not related to the trial. The difference between the experimental group and control group for 6MWT was statistically non-significant and only a small clinical effect was indicated by Cohens' d.

The secondary outcomes showed no difference between groups, except a potential difference in favour of intervention with regard to HADS-D. The intervention might have had a beneficial effect on depressive symptoms. However, it is a secondary outcome and the result should be interpreted with caution. Data from HADS was dichotomized, which produces a risk of reducing the complexity. When looking at the mean scores, there is a 0.6-point difference between the groups in favour of the intervention group. Symptoms of depression compared with anxiety are more prevalent in patients undergo-

ing CABG surgery (25), but they reported a greater reduction in symptoms after surgery compared with others undergoing open heart surgery (26). No trial has investigated the effect of psycho-education combined with physical training after CABG. A systematic review found psycho-education intervention to have a moderate effect in decreasing anxiety and depression after CABG surgery (27), which is in line with our findings.

The intervention showed no effect on self-reported physical and mental health, anxiety, pain, sleep or health-related quality of life, but there was a positive tendency in all outcomes. It is possible that the choice of primary and secondary outcomes was inadequate. The comprehensive test battery included separate valid instruments used in other rehabilitation trials. However, the order of the instruments could influence the responders' approach to the answers. Even though the instruments were different, questions sometimes looked similar, which could have been annoying for some responders. It is not obvious why changes were not found, but a plausible explanation is poor adherence to parts of the intervention. Patient adherence was high for the psycho-educational consultations. Subsequent use of the mindfulness toolbox varied greatly. In most cases the recorded mindfulness instructions were used in a few instances for a specific problem, reflecting mainly male participants' scepticism towards mindfulness (28). The sporadic use of mindfulness tools was expected given the brief rehabilitation programme. In other contexts the effect of mindfulness components requires regular practice (e.g. weekly meetings extending for 4–8 weeks after hospitalization) (29).

The per-protocol analysis showed differences between the 2 groups in 6MWT and Sit-To-Stand test, albeit with a small clinical effect expressed by Cohen's d. This suggests that non-adherence to the rehabilitation has affected our results. The findings from the experimental adherent group are identical to those of the few studies of physical training in early rehabilitation (9, 30) and the pilot test prior to this trial (13). Hence, we hypothesize that low adherence has biased the results towards null. Adherence is a known challenge in rehabilitation (31) and was highlighted in the pilot trial (13). Physiotherapists placed more emphasis on "why and how to do exercise" in this trial and the self-reported diary was simplified to enhance adherence. Further research in adherence and in the profile of non-adherent individuals is needed. The exploratory and hypothesisgenerating analysis could indicate from a comparative effectiveness research point of view that the intervention had an effect in those patients who had a certain level of participation. The per-protocol analysis showed that, for the majority of the secondary outcomes, the experimental group had a more advantageous development than the control group, resulting in a Cohen's d indicating a small clinical effect.

The complex intervention used here reflected the problems associated with CABG surgery. It was developed to be "comprehensive" and included both physical and psycho-educational components. However, the programme may have been too ambitious, because when evaluating the intervention that addresses separate components it becomes difficult to identify the specific effect of each element. Further research is needed to optimize the components of rehabilitation and to identify barriers to adherence in early rehabilitation after CABG.

Patients were included consecutively from an unselected CABG population with a number of exclusion and inclusion criteria securing external validity. The trial applied central stratified randomization to secure against selection bias, and a blinded assessment and statistical analysis to reduce detection and interpretation bias. Of the 440 eligible patients 326 were randomized, which is a high inclusion rate in rehabilitation. Participating in a clinical trial might exert an effect on the physical and mental health of patients through contact with health professionals. A concern is that the control group might have received unintended intervention during admission or at testing by the trial personal. The trial results might have been affected by the participants being aware that they were being studied or that they received additional attention. Self-reported outcomes as used in the diaries and the questionnaires are by nature subjective and therefore likely to have a risk of recall bias. Nonetheless, the patients completed the questionnaires independently of researchers.

In conclusion, the SheppHeartCABG had no effect on the primary outcome, the 6MWT, or on secondary outcomes, except that the intervention might have had a beneficial effect on depressive symptoms. Parts of the intervention were associated with a high level of non-adherence, jeopardizing the "dose" received. From the point of view of comparative effectiveness research the intervention had a positive effect for adherent participants, showing differences between the 2 groups in the physical outcomes 6MWT and Sit-To-Stand test. Furthermore, the majority of secondary outcomes in the experimental group showed a more advantageous development than in the control group. However, these differences were non-significant and had a small clinical effect.

ACKNOWLEDGEMENTS

The authors would like to thank the 326 participating patients. We further thank the test and rehabilitation team from the

Departments of Occupational Therapy and Physiotherapy at Rigshospitalet and Odense University Hospital. We thank Jette Hallberg, Graziella Zangger, Signe Gils Andersen, Karina Gregersen Jensen, Tina Torobi, Katrine Thingholm Erhardsen, Asker Kristensen and Jesper Topperup for training the patients and Peter Schmidt-Andersen, Freja Sønder, Kasper Ipsen, Jess Hasselby Nielsen, Katri Vainio-Pedersen, Camilla Nielsen and Rikke Sørensen for testing. Thanks also to Bente Birgitte Brodersen, Camilla Larsen, Tine Logan and Line Dan Jensen for conducting the psycho-educational intervention in collaboration with BB and IEH. Last but not least, we thank the steering committee.

Funding: The SheppHeartCABG has received funding from: The Heart Centre Research Foundation, Rigshospitalet, The Foundation of Cardiothoracic Surgery, Rigshospitalet, Metropolitan University College, The Lundbeck Foundation (FP 55-2013), Aase & Ejnar Danielsen Foundation (10-001245), Association Oestifterne (14-105 and 16-070), Research Foundation Rigshospitalet, and Odense Universitetshospital (13-A752).

REFERENCES

- Piepoli MF, Corra U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B, Cupples M, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol 2014; 21: 664-681.
- Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 2012; 143: 4–34.
- Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010; 17: 1-17.
- Lie I, Bunch EH, Smeby NA, Arnesen H, Hamilton G. Patients' experiences with symptoms and needs in the early rehabilitation phase after coronary artery bypass grafting. Eur J Cardiovasc Nurs 2012; 11: 14–24.
- Redeker NS, Hedges C. Sleep during hospitalization and recovery after cardiac surgery. J Cardiovasc Nurs 2002; 17: 56–68.
- Lindberg P, Gunnarsson L, Tokics L, Secher E, Lundquist H, Brismar B, et al. Atelectasis and lung function in the postoperative period. Acta Anaesthesiol Scand 1992; 36: 546–553.
- Balady GJ, Ades PA, Comoss P, Limacher M, Pina IL, Southard D, et al. Core components of cardiac rehabilitation/secondary prevention programs: a statement for healthcare professionals from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation Writing Group. Circulation 2000; 29; 1069–1073.
- Pescatello, LS, Arena, R. Riebe, D, Thompson, PD., editor. ACSM's Guidelines for exercise testing and prescription. Ninth edition ed. Baltimore; Wolthers Kluwer, Lippincott Williams & Wilkins: American College of Sports Medicine

- 2013.
- Hirschhorn AD, Richards DA, Mungovan SF, Morris NR, Adams L. Does the mode of exercise influence recovery of functional capacity in the early postoperative period after coronary artery bypass graft surgery? A randomized controlled trial. Interact Cardiovasc Thorac Surg 2012; 15: 995–1003.
- Freitas ER, Soares BG, Cardoso JR, Atallah AN. Incentive spirometry for preventing pulmonary complications after coronary artery bypass graft. Cochrane Database Syst Rev. 2012: 12: 9.
- 11. Berg S, Kikkenborg. Comprehensive rehabilitation for patients with ICD. [dissertation]. Aarhus University 2011.
- Stroobant N, Vingerhoets G. Depression, anxiety, and neuropsychological performance in coronary artery bypass graft patients: a follow-up study. Amsterdam; Psychosomatics 2008; 49: 326–331.
- Hojskov IE, Moons P, Hansen NV, Greve H, Olsen DB, Cour S, et al. Early physical training and psycho-educational intervention for patients undergoing coronary artery bypass grafting. The SheppHeart randomized 2 x 2 factorial clinical pilot trial. Eur J Cardiovasc Nurs 2016: 15: 425–437.
- Hojskov IE, Moons P, Hansen NV, La Cour S, Olsen PS, Gluud C, et al. SheppHeartCABG trial-comprehensive early rehabilitation after coronary artery bypass grafting: a protocol for a randomised clinical trial. BMJ Open 2017; 17: e013038.
- Parse R. The human becoming school of thought: a perspective for nurses and other health professionals. Thousand Oaks, CA: Stage; 1998.
- Martin, C.G., Turkelson, S.L. Nursing care of the patient undergoing coronary artery bypass grafting. J Cardiovasc Nurs 2006: 21: 109–117.
- 17. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001; 119: 256–270.
- 18. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111–117.
- 19. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220–233.
- Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52: 69–77.
- 21. Oldridge N, Hofer S, McGee H, Conroy R, Doyle F, Saner H, et al. The HeartQoL: part II. Validation of a new core health-related quality of life questionnaire for patients with ischemic heart disease. Eur J Prev Cardiol 2014; 21: 98–106.
- 22. Buysse DJ, Reynolds CF,3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193–213.
- Sattelmayer M, Lorenz T, Roder C, Hilfiker R. Predictive value of the Acute Low Back Pain Screening Questionnaire and the Orebro Musculoskeletal Pain Screening Questionnaire for persisting problems. Eur Spine J 2012; 21: 773-784.
- 24. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport 1999; 70: 113–119.
- Tully PJ, Baker RA. Depression, anxiety, and cardiac morbidity outcomes after coronary artery bypass surgery: a contemporary and practical review. J Geriatr Cardiol 2012; 9: 197–208.
- 26. Protogerou C, Fleeman N, Dwan K, Richardson M, Dundar Y, Hagger MS. Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis. Behav

- Res Ther 2015; 73: 151-164.
- 27. Whalley B, Rees K, Davies P, Bennett P, Ebrahim S, Liu Z, et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev 2011; 10: CD002902.
- 28. Grossman P. Mindfulness for Psychologists: Paying Kind Attention to the Perceptible. Mindfulness 2010; 1: 87-97.
- 29. Carmody J, Baer RA. How long does a mindfulness-based stress reduction program need to be? A review of class contact hours and effect sizes for psychological distress.
- J Clin Psychol 2009; 65: 627-638.
- 30. Hirschhorn AD, Richards D, Mungovan SF, Morris NR, Adams L. Supervised moderate intensity exercise improves distance walked at hospital discharge following coronary artery bypass graft surgery - a randomised controlled trial. Heart Lung Circ 2008; 17: 129-138.
- 31. Jack K, McLean SM, Moffett JK, Gardiner E. Barriers to treatment adherence in physiotherapy outpatient clinics: a systematic review. Man Ther 2010; 15: 220-228.